story of the week
Fixed-Dose Combined Pertuzumab/Trastuzumab for Subcutaneous Injection Plus Chemotherapy in HER2+ Early Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection Plus Chemotherapy in HER2-Positive Early Breast Cancer (FeDeriCa): A Randomised, Open-Label, Multicentre, Non-Inferiority, Phase 3 Study
Lancet Oncol 2020 Dec 17;[EPub Ahead of Print], AR Tan, SA Im, A Mattar, R Colomer, D Stroyakovskii, Z Nowecki, M De Laurentiis, JY Pierga, KH Jung, C Schem, A Hogea, T Badovinac Crnjevic, S Heeson, M Shivhare, WP Kirschbrown, E Restuccia, C JackischFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.